AIDX (AIDX)
0.48
-0.04 (7.69%)
Upcoming Events
Latest Headlines
HEALWELL's DARWEN(TM) AI Outperforms Published Foundation Model Benchmarks and Demonstrates Real-World Patient Impact in New Peer-Reviewed Research
September 15, 2026 6:02 AM - StreetInsider
Form 8-K 20/20 Biolabs, Inc. For: Sep 03
September 10, 2026 4:11 PM - SEC Filing
Healwell's Darwen AI to match clinical trials to 100K+ consented patients
September 8, 2026 6:34 AM - StreetInsider
WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents
September 8, 2026 6:32 AM - StreetInsider
HEALWELL's DARWEN(TM) to Power AI-Driven Clinical Trial Matching for WELLTRUST(TM), a Network of Over 100,000 Consented Patients
September 8, 2026 6:32 AM - StreetInsider
HEALWELL to Deploy AI-Powered SMART Search and SMART Summary Across Statewide U.S. Health Information Exchange
September 1, 2026 6:02 AM - StreetInsider
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 28, 2026 6:26 PM - Globe NewsWire
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
August 26, 2026 8:31 AM - StreetInsider
Form DEFA14A 20/20 Biolabs, Inc.
August 19, 2026 4:51 PM - SEC Filing
Form 8-K 20/20 Biolabs, Inc. For: Aug 18
August 19, 2026 9:19 AM - SEC Filing
Form 424B3 20/20 Biolabs, Inc.
August 17, 2026 4:15 PM - SEC Filing
Form 424B3 20/20 Biolabs, Inc.
August 17, 2026 4:10 PM - SEC Filing
Form 8-K 20/20 Biolabs, Inc. For: Aug 17
August 17, 2026 4:06 PM - SEC Filing
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
August 17, 2026 8:31 AM - StreetInsider
Form 10-Q 20/20 Biolabs, Inc. For: Jun 30
August 14, 2026 4:13 PM - SEC Filing
Form 8-K 20/20 Biolabs, Inc. For: Aug 05
August 5, 2026 12:01 PM - SEC Filing
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
July 30, 2026 8:31 AM - StreetInsider
20/20 BioLabs meets with East Asia partners to explore expansion
July 27, 2026 4:30 PM - StreetInsider
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
July 27, 2026 4:30 PM - StreetInsider
20/20 BioLabs reaches standstill deal on Series E preferred stock
July 23, 2026 8:32 AM - StreetInsider
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
July 23, 2026 8:31 AM - StreetInsider
Form 8-K 20/20 Biolabs, Inc. For: Jul 16
July 22, 2026 4:45 PM - SEC Filing
20/20 BioLabs reports Q2 revenue growth, outlines Medicare strategy
July 9, 2026 4:01 PM - StreetInsider
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
July 9, 2026 4:01 PM - StreetInsider
Form 8-K 20/20 Biolabs, Inc. For: Jul 01
July 1, 2026 3:29 PM - SEC Filing
Form DEFA14A 20/20 Biolabs, Inc.
June 23, 2026 5:03 PM - SEC Filing
Form DEF 14A 20/20 Biolabs, Inc. For: Aug 18
June 23, 2026 5:02 PM - SEC Filing
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
June 22, 2026 4:45 PM - StreetInsider
Full Article List